Human papillomavirus in metastatic lymph nodes from unknown primary head and neck squamous cell carcinoma

Otolaryngol Head Neck Surg. 2011 Jul;145(1):51-7. doi: 10.1177/0194599811400385.

Abstract

Objective: Determine human papillomavirus (HPV) incidence in unknown primary squamous cell carcinomas (SCCa) of the head and neck and assess if HPV status influenced survival.

Study design: Historical cohort study.

Setting: Tertiary care center.

Subjects: Patients with unknown primary SCCa despite a complete workup who underwent neck dissection or excisional biopsy and postoperative comprehensive ± chemoradiotherapy between 2002 and 2009.

Methods: HPV fluorescence in situ hybridization (FISH) and p16(INK4a) immunohistochemistry (p16 IHC) were performed. Results were compared with survival, age, race, gender, tobacco use, alcohol use, and nodal stage.

Results: Twenty-five patients met the inclusion criteria, of whom 88% were >10 pack year tobacco users. Twenty-eight percent were HPV-positive defined by both p16+ and FISH+. Five-year overall survival was 66.7% in HPV-positive and 48.5% in HPV-negative patients (P = .35). Similarly, 5-year disease-free survival rates were 66.7% in HPV-positive and 48.5% in HPV-negative patients (P = .54). All 3 HPV-positive nonsmokers were survivors, but this was not significant because of the small sample size (P > .05). No other characteristics were associated with survival (P > .05).

Conclusion: Twenty-eight percent of metastatic lymph nodes from occult primary tumors were HPV positive. There was no survival difference associated with HPV status. Most of the HPV-positive patients in this study were tobacco users who had similar survival to HPV-negative patients, so caution should be used in interpreting HPV status in these patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Biopsy
  • Carcinoma, Squamous Cell / mortality
  • Carcinoma, Squamous Cell / pathology*
  • Carcinoma, Squamous Cell / secondary*
  • Carcinoma, Squamous Cell / therapy
  • Carcinoma, Squamous Cell / virology*
  • Combined Modality Therapy
  • Cyclin-Dependent Kinase Inhibitor p16 / analysis
  • Disease-Free Survival
  • Female
  • Follow-Up Studies
  • Human papillomavirus 16*
  • Humans
  • Immunoenzyme Techniques
  • In Situ Hybridization, Fluorescence
  • Kaplan-Meier Estimate
  • Lymph Nodes
  • Lymphatic Metastasis / pathology*
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Neoplasms, Unknown Primary / mortality
  • Neoplasms, Unknown Primary / pathology*
  • Neoplasms, Unknown Primary / therapy
  • Neoplasms, Unknown Primary / virology*
  • Otorhinolaryngologic Neoplasms / mortality
  • Otorhinolaryngologic Neoplasms / pathology*
  • Otorhinolaryngologic Neoplasms / secondary*
  • Otorhinolaryngologic Neoplasms / therapy
  • Otorhinolaryngologic Neoplasms / virology*
  • Papillomavirus Infections / pathology*
  • Papillomavirus Infections / surgery
  • Papillomavirus Infections / virology*
  • Smoking / adverse effects
  • Smoking / pathology

Substances

  • Cyclin-Dependent Kinase Inhibitor p16